Get the Stockscreener App
4.70
10.13%
-0.53
Pre-market:
4.72
0.02
+0.43%
Prelude Therapeutics Inc stock is traded at $4.70, with a volume of 1.11M.
It is down -10.13% in the last 24 hours and up +36.23% over the past month.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
See More
Previous Close:
$5.23
Open:
$5.18
24h Volume:
1.11M
Relative Volume:
3.07
Market Cap:
$374.32M
Revenue:
$12.14M
Net Income/Loss:
$-99.50M
P/E Ratio:
-3.472
EPS:
-1.3537
Net Cash Flow:
$-56.37M
1W Performance:
+0.00%
1M Performance:
+36.23%
6M Performance:
+195.60%
1Y Performance:
+411.76%
1-Day Range:
$4.50
$5.26
1-Week Range:
$4.04
$5.26
52-Week Range:
$0.73
$5.54
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.70 | 374.32M | 12.14M | -99.50M | -56.37M | -1.3537 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat
Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo
Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com - Investing.com South Africa
Orbimed entities acquire $12.5m in Prelude Therapeutics stock - Investing.com
OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan
OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy - Stock Titan
Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital - TradingView
Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f - GuruFocus
Prelude Therapeutics (PRLD) Launches $90M Public Offering with S - GuruFocus
Prelude Therapeutics Shares Rise on Positive Preclinical Data for Breast Cancer Drug - Moomoo
Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12 - Minichart
Prelude Therapeutics prices $90M equity offering - MSN
Prelude Therapeutics prices $90M stock offering at $4.44/share By Investing.com - Investing.com Canada
Prelude Therapeutics presents preclinical data on breast cancer drug By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - ChartMill
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com - Investing.com Australia
Prelude Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer to Advance Precision Oncology Pipeline - Minichart
Prelude Therapeutics (PRLD) Appoints New Chief Medical Officer - GuruFocus
Prelude Therapeutics Appoints Veteran Oncologist as New CMO - TipRanks
Prelude Therapeutics names Charles Morris as chief medical officer - Investing.com
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - The Manila Times
New CMO joins Prelude Therapeutics (NASDAQ: PRLD) as pipeline advances - Stock Titan
Bull Bear: Is Prelude Therapeutics Incorporated stock a good pick for beginners2026 Stock Rankings & Capital Efficiency Focused Ideas - baoquankhu1.vn
Activity Recap: Whats the beta of Prelude Therapeutics Incorporated stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Aug Swings: What is the Moat Score of Prelude Therapeutics Incorporated2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 4.3%Still a Buy? - MarketBeat
Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Is Prelude (PRLD) Stock Declining | Price at $4.08, Down 7.27%Continuation Signals - Newser
Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN
PRLD Technical Analysis & Stock Price Forecast - Intellectia AI
Rate Hike: Is Prelude Therapeutics Incorporated backed by strong institutional buying2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):